newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

  • bioAffinity Technologies (NASDAQ: BIAF, BIAFW) regained compliance with Nasdaq listing requirements & will continue trading on the Nasdaq Capital Market.
  • Nasdaq confirmed compliance with Listing Rule 5550(a)(2) regarding the minimum bid price of $1.00 per share & Listing Rule 5560(a) regarding rights & warrants.
  • The scheduled hearing before the Nasdaq Hearings Panel was cancelled as a result of the compliance determination.
  • The company's CyPath Lung test utilizes flow cytometry & proprietary AI to detect lung cancer in high-risk patients with 92% sensitivity & 87% specificity.
  • CyPath Lung is marketed as a Laboratory Developed Test (LDT) under CLIA regulations by subsidiary Precision Pathology Laboratory Services.
  • President & CEO Maria Zannes stated that maintaining the listing supports the expansion of CyPath Lung access & the development of the broader noninvasive healthcare pipeline.